Luengo M, Picado C, Del Rio L, Guañabens N, Montserrat J M, Setoain J
Servei de Pneumologia, Hospital Clinic, Facultat de Medicina, Barcelona, Spain.
Thorax. 1991 Nov;46(11):803-6. doi: 10.1136/thx.46.11.803.
Reduced bone mass predisposes patients to the development of vertebral fractures. Measurement of bone mass by non-invasive methods is used to detect patients with involutional osteoporosis at risk from fractures. These methods have not been assessed in patients with steroid dependent osteoporosis. The objective of this study was to assess the value of a predictive fracture threshold value of bone density in patients with steroid dependent asthma.
Three groups of patients were studied. Group 1 (67 patients) had steroid dependent asthma (mean daily dose of prednisone 11.7 mg) and no vertebral fractures, group 2 (32 patients) had steroid dependent asthma (mean daily dose of prednisone 12 mg) and vertebral fractures, and group 3 (55 patients) were not taking steroids but had involutional osteoporosis and a recent non-traumatic vertebral fracture. Bone mineral density was measured by dual photon absorptiometry and vertebral fractures by radiography of the lumbar spine. A fracture threshold was determined in the two groups with fractures as the 90th percentile of the mean bone mineral density measured in the lumbar spine.
Bone mineral density was significantly higher in the steroid dependent group with fractures (group 2) than in group 3 patients, who had involutional osteoporosis and fractures (0.946 (0.18) g/cm2 v 0.830 (0.16) g/cm2). The fracture threshold value was therefore higher for patients with steroid related vertebral fractures (group 2, 1.173 g/cm2) than for those with involutional osteoporosis (group 3, 0.979 g/cm2). Vertebral fractures were more likely to occur in steroid dependent asthmatic patients with bone density above the fracture threshold value (obtained from subjects with involutional osteoporosis) than in subjects in group 3 (34% v 9%).
Vertebral fractures occur in patients treated with steroids in the presence of higher bone mineral density than is the case with patients with involutional osteoporosis. The findings suggests that the assessment of the efficacy of preventive treatment requires measurement of bone mineral density and radiology.
骨量减少使患者易发生椎体骨折。通过非侵入性方法测量骨量用于检测有骨折风险的退行性骨质疏松症患者。这些方法尚未在类固醇依赖性骨质疏松症患者中进行评估。本研究的目的是评估骨密度预测骨折阈值在类固醇依赖性哮喘患者中的价值。
研究了三组患者。第1组(67例患者)患有类固醇依赖性哮喘(泼尼松平均日剂量11.7毫克)且无椎体骨折,第2组(32例患者)患有类固醇依赖性哮喘(泼尼松平均日剂量12毫克)且有椎体骨折,第3组(55例患者)未服用类固醇但患有退行性骨质疏松症且近期有非创伤性椎体骨折。通过双能光子吸收法测量骨矿物质密度,通过腰椎X线摄影检测椎体骨折。以两组有骨折患者的腰椎平均骨矿物质密度的第90百分位数确定骨折阈值。
有骨折的类固醇依赖组(第2组)的骨矿物质密度显著高于患有退行性骨质疏松症且有骨折的第3组患者(0.946(0.18)克/平方厘米对0.830(0.16)克/平方厘米)。因此,与退行性骨质疏松症患者(第3组,0.979克/平方厘米)相比,类固醇相关椎体骨折患者(第2组,1.173克/平方厘米)的骨折阈值更高。骨密度高于骨折阈值(取自退行性骨质疏松症患者)的类固醇依赖性哮喘患者比第3组患者更易发生椎体骨折(34%对9%)。
与退行性骨质疏松症患者相比,接受类固醇治疗的患者在骨矿物质密度较高的情况下会发生椎体骨折。研究结果表明,预防性治疗疗效的评估需要测量骨矿物质密度并进行放射学检查。